“The power of AI in diagnostic imaging grows when the patient journey is monitored and measured. Combining Bialogics AIQ framework with the ClearReadTM CT nodule detection and analysis tools brings new visibility into the performance of the tool and the patient journey of those with lung cancer and, in the future, other lung health applications,”

Steve Worrell, CEO, Riverain Technologies.